Summit Therapeutics Inc.

NasdaqGM:SMMT 株式レポート

時価総額：US$14.0b

Summit Therapeutics マネジメント

マネジメント 基準チェック /24

Summit Therapeuticsの CEO はBob Dugganで、 Jul2022年に任命され、 の在任期間は 2.33年です。 は、会社の株式の74.81%を直接所有しており、その価値は$ 10.48B 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と4.5年です。

主要情報

Bob Duggan

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間2.3yrs
CEOの所有権74.8%
経営陣の平均在職期間2.5yrs
取締役会の平均在任期間4.5yrs

経営陣の近況

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics May Have Further Upside From Here

Aug 03

Summit Therapeutics Stock: Plunging Despite A Win?

May 31

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

May 06

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Jan 30

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

CEO（最高経営責任者

Bob Duggan (80 yo)

2.3yrs

在職期間

Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Robert Duggan
Co-CEO & Executive Chairman2.3yrsデータなし74.81%
$ 10.5b
Mahkam Zanganeh
Co-CEO, President & Director2.3yrsUS$20.56m4.85%
$ 679.0m
Manmeet Soni
COO, CFO & Director1.1yrsUS$23.97m0.41%
$ 57.4m
Dame Davies
Co-Founderno dataデータなしデータなし
Bhaskar Anand
Chief Accounting Officer & Head of Financeless than a yearデータなし0.018%
$ 2.5m
Divya Chari
Head of Global Clinical Operations4.7yrsデータなしデータなし
Dave Gancarz
Chief Business & Strategy Officerno dataデータなしデータなし
Betty Chang
Head of Research3.4yrsデータなしデータなし
Fong Clow
Chief Biometrics Officer3.8yrsデータなしデータなし
Shelley Spray
Chief Education & Brand Officer1.8yrsデータなしデータなし
Juthamas Sukbuntherng
Head of Clinical Pharmacology & DMPK3.3yrsデータなしデータなし
Urte Gayko
Chief Regulatory2.6yrsUS$609.86kデータなし

2.5yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: SMMTの経営陣は 経験豊富 であると考えられます ( 2.5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Robert Duggan
Co-CEO & Executive Chairman4.9yrsデータなし74.81%
$ 10.5b
Mahkam Zanganeh
Co-CEO, President & Director4yrsUS$20.56m4.85%
$ 679.0m
Manmeet Soni
COO, CFO & Director4.9yrsUS$23.97m0.41%
$ 57.4m
Dame Davies
Co-Founderno dataデータなしデータなし
Kenneth Clark
Lead Independent Director3.1yrsUS$334.65kデータなし
Marcel van den Heuvel
Member of Scientific Advisory Boardno dataデータなしデータなし
Francesco Muntoni
Member of Scientific Advisory Boardno dataデータなしデータなし
Roger Patient
Member of Scientific Advisory Boardno dataデータなしデータなし
Edith Sim
Member of Scientific Advisory boardno dataデータなしデータなし
Bob Sim
Member of Scientific Advisory boardno dataデータなしデータなし
Derek Stemple
Member of Scientific Advisory boardno dataデータなしデータなし
Jean-Paul Vincent
Member of Scientific Advisory boardno dataデータなしデータなし

4.5yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: SMMTの 取締役会 は 経験豊富 であると考えられます ( 4.5年の平均在任期間)。